CoChat

Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction

Open access
Razvi, Salman, Bhana, Sindeep, Mrabeti, Sanaa · 2019 · Journal of Thyroid Research

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 9 of the 87 sources its claims cite were checked for support.

Abstract

The pituitary hormone, thyrotropin (TSH), is regarded as the primary biomarker for evaluating thyroid function and is useful in guiding treatment with levothyroxine for patients with hypothyroidism. The amplified response of TSH to slight changes in thyroid hormone levels provides a large and easily measured signal in the routine care setting. Laboratories provide reference ranges with upper and lower cutoffs for TSH to define normal thyroid function. The upper limit of the range, used to diagnose subclinical (mild) hypothyroidism, is itself a matter for debate, with authoritative guidelines recommending treatment to within the lower half of the range. Concomitant diseases, medications, supplements, age, gender, ethnicity, iodine status, time of day, time of year, autoantibodies, heterophilic antibodies, smoking, and other factors influence the level of TSH, or the performance of current TSH assays. The long-term prognostic implications of small deviations of TSH from the reference range are unclear. Correction of TSH to within the reference range does not always bring thyroid and other biomarkers into range and will not always resolve the patient’s symptoms. Overt hypothyroidism requires intervention with levothyroxine. It remains important that physicians managing a patient with symptoms suggestive of thyroid disease consider all of the patient’s relevant disease, lifestyle, and other factors before intervening on the basis of a marginally raised TSH level alone. Finally, these limitations of TSH testing mitigate against screening the population for the undoubtedly substantial prevalence of undiagnosed thyroid disease, until appropriately designed randomised trials have quantified the benefits and harms from this approach.

Overview

CoChat Summary

TL;DR

This narrative review argues that TSH is the primary biomarker for thyroid dysfunction but that its interpretation is complicated by demographic, disease, medication, assay, and temporal factors, and by uncertain reference-range cutoffs. It concludes that clinicians should not treat a marginally raised TSH alone and that population screening lacks sufficient evidence.

Key findings

  • Guidelines cite an adult TSH reference and therapeutic target range of 0.4–4.0 mIU/mL; subclinical hypothyroidism is TSH above the reference with normal thyroid hormones, and NICE recommends controlling TSH to 0.4–2.5 mIU/L for most people with treated subclinical hypothyroidism.
  • TSH upper reference limits vary with age: in about 150,000 thyroid antibody-negative people, the 97.5th percentile increased from 3.98 mIU/L at age 31–40 to 5.94 mIU/L at age >90 years; higher TSH is also seen in women and in some ethnic groups.
  • Many factors affect TSH or TSH assays, including medications/supplements (e.g., metformin lowers TSH), assay interference estimated in almost 1% of all thyroid function tests, macro-TSH, heterophilic antibodies, biotin, diurnal/circannual variation, pregnancy, obesity, smoking, and endocrine disruptors.
  • Small TSH elevations may resolve: 37/40 people with subclinical hypothyroidism (TSH >5 mIU/L) reverted to normal over 5 years; undiagnosed thyroid disease prevalence was about 6% in NHANES III and about 5% undiagnosed hypothyroidism and 2% undiagnosed hyperthyroidism in a European meta-analysis, but screening is not supported by current evidence.

Methods

  • Narrative review summarizing the evidence-based rationale for current thyroid testing and common pitfalls in interpreting TSH results.
  • No primary data or systematic sample; it draws on published studies, guidelines, and reviews, including large population cohorts and meta-analyses.
  • Main analysis is a qualitative synthesis of factors affecting TSH and reference ranges; no meta-analysis or formal risk-of-bias assessment is described.

Limitations

  • The paper states that the upper TSH cutoff best predicting prognosis remains uncertain, the long-term prognostic implications of small TSH deviations are unclear, evidence is insufficient for population screening and for individualized/optimal TSH ranges, and easily measurable biomarkers of tissue thyroid hormone status are needed.
  • Evident from the text: as a narrative review, it does not report a systematic search strategy, study selection, or quality appraisal, and it presents no primary data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1155/2019/4106816

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Overview of common factors that can produce an aberrant TSH test. aMetformin reduces serum TSH in people with overt or subclinical hypothyroidism and in euthyroid individuals with high normal baseline TSH levels (see refs [31] and [32]; see text for other references). HAMA: human anti-mouse antibody; RF: rheumatoid factor; TSH: thyrotropin.
Figure 1 Overview of common factors that can produce an aberrant TSH test. aMetformin reduces serum TSH in people with overt or subclinical hypothyroidism and in euthyroid individuals with high normal baseline TSH levels (see refs [31] and [32]; see text for other references). HAMA: human anti-mouse antibody; RF: rheumatoid factor; TSH: thyrotropin.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 4 Not valid · 56 Not checked · 17 Own results and interpretations

22 more claims

Create a free account to see all 85 claims and to verify the 78 references still open.

See all claims — free account
  • It may state two separate claims as one. 32
  • Probably not a substantial claim. 36

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 63 references

Research works printed but not linked: 4

  1. Shahid M. A. Sharma S. Physiology, Thyroid Hormone 2019 Treasure Island, FL, USA Stat Pearls https://www.ncbi.nlm.nih.gov/books/NBK500006
  2. Spencer C. A. De Groot L. J. Chrousos G. Dungan K. Assay of Thyroid Hormones and Related Substances 2017 San Francisco, CA, USA South Dartmouth: MDText.com, Inc. https://www.thyroidmanager.org/chapter/assay-of-thyroid-hormones-and-related-substances3
  3. Warade J. Pandey A. Diurnal variation of TSH: factor affecting interpretation of test Journal of Pharmaceutical and Biomedical Analysis 2014 04 9 776 780
  4. Helfand M. Stone M. B. Wallace R. B. Appendix B. Screening for thyroid disease: systematic evidence review Medicare Coverage of Routine Screening for Thyroid Dysfunction. Institute of Medicine (US) Committee on Medicare Coverage of Routine Thyroid Screening 2003 Washington, DC, USA National Academies Press (US) https://www.ncbi.nlm.nih.gov/books/NBK221542/ 25057658

Cited by

See all 90

Metadata

Authors
Razvi, S., Bhana, S., & Mrabeti, S.
Affiliations
  • Newcastle University (GB)
  • University of the Witwatersrand (ZA)
  • Medical Affairs EMEA, Merck Serono Middle East FZ-LLC, Dubai, UAE
Corresponding author
Razvi, Salman
Venue
Journal of Thyroid Research
Publisher
Wiley
Published
2019-09-22
Volume
2019
Pages
1-8
ISSN
  • 2042-0072 (ISSN-L)
  • 2090-8067
OpenAlex
W2972101486
Cited by
90
References
63
Citations by year
2026: 8 · 2025: 13 · 2024: 15 · 2023: 14 · 2022: 13 · 2021: 17 · 2020: 10
FWCI
1.54
Type
journal article
Language
en
Open access
Locations
  • Journal of Thyroid Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
Keywords
thyroid-stimulating hormone, TSH reference range, subclinical hypothyroidism, hypothyroidism diagnosis, levothyroxine, heterophile antibodies, thyroid autoantibodies, overt hypothyroidism, thyroid screening, thyroid function tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction. https://app.cochat.ai/papers/10.1155/2019/4106816
The paper
Razvi, S., Bhana, S., & Mrabeti, S. (2019). Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction. Journal of Thyroid Research. https://doi.org/10.1155/2019/4106816

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.